We are live on ! Find out more
ASBPW

Aspire Biopharma Warrant
ASBPW

36 hedge funds and large institutions have $7.27M invested in Aspire Biopharma Warrant in 2022 Q2 according to their latest regulatory filings, with 36 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
36
Holders Change
+36
Holders Change %
–
% of All Funds
0.61%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
36
Increased
–
Reduced
–
Closed
–
Calls
$2.1M
Puts
–
Net Calls
+$2.1M
Net Calls Change
+$2.1M

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$228K
2
SCM
Saba Capital Management
New York
+$214K
3
LA
Linden Advisors
New York
+$196K
4
AA
AQR Arbitrage
Connecticut
+$146K
5
SC
Sculptor Capital
New York
+$109K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Verition Fund Management
1
Verition Fund Management
Connecticut
$4.4M +$95.9K +440,721 New
RCM
2
Radcliffe Capital Management
Pennsylvania
$1.5M +$32.6K +150,000 New
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$179K +$228K +1,050,000 New
HCM
4
Highbridge Capital Management
New York
$161K – – –
SCM
5
Saba Capital Management
New York
$157K +$214K +983,603 New
LA
6
Linden Advisors
New York
$144K +$196K +899,999 New
SC
7
Sculptor Capital
New York
$80K +$109K +500,000 New
AA
8
AQR Arbitrage
Connecticut
$80K +$146K +669,998 New
WAM
9
Wolverine Asset Management
Illinois
$68K +$88.3K +405,871 New
PC
10
Periscope Capital
Ontario, Canada
$63K +$80.2K +368,600 New
Barclays
11
Barclays
United Kingdom
$60K +$76.1K +350,000 New
KC
12
Kepos Capital
New York
$60K +$76.1K +350,000 New
TCA
13
Taconic Capital Advisors
New York
$36K +$65.3K +300,000 New
SRCM
14
Sage Rock Capital Management
New York
$31K +$39.9K +183,647 New
CCM
15
Context Capital Management
California
$30K +$38.1K +175,000 New
PAMP
16
Polar Asset Management Partners
Ontario, Canada
$24K +$30.1K +138,536 New
D.E. Shaw & Co
17
D.E. Shaw & Co
New York
$24K +$43.5K +199,999 New
Balyasny Asset Management
18
Balyasny Asset Management
Illinois
$24K +$43.5K +200,000 New
WA
19
Whitebox Advisors
Minnesota
$21K +$27.2K +125,000 New
Nomura Holdings
20
Nomura Holdings
Japan
$21K +$32.6K +150,000 New
WP
21
Woodline Partners
California
$17K +$21.8K +100,000 New
CCM
22
CAAS Capital Management
New York
$13K +$16.3K +75,000 New
DCM
23
Difesa Capital Management
New York
$13K +$16.3K +75,000 New
PMAM
24
Picton Mahoney Asset Management
Ontario, Canada
$12K +$16.3K +75,000 New
Hudson Bay Capital Management
25
Hudson Bay Capital Management
Connecticut
$12K +$21.2K +97,474 New
1
2

ASBPW Hedge Fund Activity: Q2 2022 in Review

36 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q2 2022, worth a combined $7.27M.

Buyers outnumbered sellers: 36 funds opened new ASBPW positions and 0 closed out — a net gain of 36 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $228K.

  • 36 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q2 2022, up from 0 in Q1 2022.
  • Funds reported $7.27M of Aspire Biopharma Warrant stock for Q2 2022.
  • 36 funds opened new Aspire Biopharma Warrant positions in Q2 2022 and 0 closed out, a net change of +36 holders.
  • The largest Aspire Biopharma Warrant buyer in Q2 2022 was Adage Capital Partners, an estimated $228K added.

Based on aggregated 13F filings for Q2 2022.